[go: up one dir, main page]

WO1993016715A1 - Facteur 1 de stimulation de fibroblastes et detection anticipee de la fibrose - Google Patents

Facteur 1 de stimulation de fibroblastes et detection anticipee de la fibrose Download PDF

Info

Publication number
WO1993016715A1
WO1993016715A1 PCT/US1993/001554 US9301554W WO9316715A1 WO 1993016715 A1 WO1993016715 A1 WO 1993016715A1 US 9301554 W US9301554 W US 9301554W WO 9316715 A1 WO9316715 A1 WO 9316715A1
Authority
WO
WIPO (PCT)
Prior art keywords
fsf
polypeptide
sample
fibrotic scarring
antibody
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US1993/001554
Other languages
English (en)
Inventor
David Wyler
Sadhana Prakash
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Tufts Medical Center Inc
Original Assignee
New England Medical Center Hospitals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by New England Medical Center Hospitals Inc filed Critical New England Medical Center Hospitals Inc
Publication of WO1993016715A1 publication Critical patent/WO1993016715A1/fr
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/24—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against cytokines, lymphokines or interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475—Growth factors; Growth regulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/52—Cytokines; Lymphokines; Interferons
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/22—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against growth factors ; against growth regulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
    • Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
    • Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
    • Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
    • Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change

Definitions

  • mice Animals and Schistosomiasis infection C57BL/6NcrLBr female mice (18 to 20 g; Taconic Farms, Inc., Germantown, NY) were infected by the intraperitoneal injection of 35-50 cercariae of S. mansoni (Puerto Guatemalan strain) suspended in 0.5 ml sterile saline. The mice were euthanized eight weeks later by inducing C0 2 narcosis and their livers were placed in cold Hanks'' buffered salt solution (HBSS) . Isolation of granulomas and preparation of crranuloma supernatant. Isolation of granulomas was performed as described previously (Wyler et al. , Science.
  • Antibody-treated cells were sorted FACStar Plus flow cytometry and analyzed by a FACScan (Becton- Dickinson) or a Coulter Epics 541 (Coulter Electronics Inc. , Hialeah, FL) flow cytometer. The fields were gaited to exclude autofluorescent and dead cells.
  • the CD4+ sorted cells were washed and suspended (0.6-1.0 x 10 6 /ml) in serum-free medium RPMI 1640 supplemented with 0.3 g/ml bovine serum albumin (BSA; Sigma, St. Louis, MO) and incubated for 24h at 30°C in 5% C0 2 - 95% air humid atmosphere.
  • BSA bovine serum albumin
  • the beads were pelleted (12,000 g x 5 min) , washed twice in phosphate-buffered 0.15 M NaCl and then boiled for 5 min in sample buffer (lOmM Tris-HCl; 2% sodium dodecyl sulfate; 5% glycerol; 2% dithiothreitol; 0.05% pyronin Y; pH 6.8). Supernatant from these treated beads were subjected to electrophoresis in a 70 x 70 x 0.5 ui slab gel of 10% acrylamide (BioRad Labs, Richmond, CA) using standard method (Laemmli, Nature 227:680 (1970)).
  • proteins were transferred electrophoretically (l-2h; 70 volts) onto nitrocellulose paper (BioRad) using standard procedures.
  • the nitrocellulose paper was then exposed to X-ray film (X- OMAT, AR; Kodak, Rochester, NY) for 72 h at -70°C.
  • Anti-FSF-1 antibody detected FSF-1 in both purified form and in crude granuloma supernatant in a dot-blot ELISA assay (Fig. 5) .
  • the antibody did not detect acidic FGF or PDGF, mitogens that were detected with the appropriate homologous antibodies (Fig. 5) .
  • CD4 + cells are stimulated "" in vivo to produce FsF-1 in response to egg antigens. Based on our current observation, such production may continue at least briefly when the lymphocytes are dissociated from the eggs and antigen-presenting cells.
  • FsF-1 not only is secreted but also can remain associated with the surface of CD4 + lymphocytes suggests that in addition to the action of the secreted cytokine, direct contact between membrane-associated FsF-1 positive lymphocytes and fibroblasts might stimulate fibroblast growth.
  • fibroblast growth factors some of which were purified from other sources and were recognized for this biological property (PDGF [Ross et al.. Cell 46:155 (1986)], FGF [Gospodarowicz et al. , J. Biol. Chem. 250:2515 (1975); Gospodarowicz et al. , J. Biol. 253.:3736 (1978)]), and heparin-binding epidermal growth factor [HB-EGF;Higashiyama et al.

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Biophysics (AREA)
  • General Health & Medical Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Immunology (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)

Abstract

Procédé d'identification d'individus susceptibles de présenter une cicatrisation due à la fibrose. Le procédé consiste à prélever un échantillon chez un individu atteint d'une maladie inflammatoire chronique, à mettre l'échantillon en contact avec un anticorps spécifique au facteur 1 de stimulation de fibroblastes (FSF-1) dans des conditions permettant la formation d'un complexe immun, et à détecter l'éventuelle augmentation du taux relatif du complexe immun, laquelle indiquerait une vulnérabilité à la cicatrisation due à la fibrose. On a également prévu des polypeptides de FSF-1 et des anticorps spécifiques au FSF-1.
PCT/US1993/001554 1992-02-24 1993-02-19 Facteur 1 de stimulation de fibroblastes et detection anticipee de la fibrose Ceased WO1993016715A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US840,426 1977-10-07
US84042692A 1992-02-24 1992-02-24

Publications (1)

Publication Number Publication Date
WO1993016715A1 true WO1993016715A1 (fr) 1993-09-02

Family

ID=25282348

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US1993/001554 Ceased WO1993016715A1 (fr) 1992-02-24 1993-02-19 Facteur 1 de stimulation de fibroblastes et detection anticipee de la fibrose

Country Status (1)

Country Link
WO (1) WO1993016715A1 (fr)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1996026954A1 (fr) * 1995-02-28 1996-09-06 New England Medical Center Hospitals, Inc. Fsf-1 et la detection precoce des fibroses
US6017719A (en) * 1994-06-14 2000-01-25 Nexell Therapeutics, Inc. Positive and positive/negative cell selection mediated by peptide release
US6214968B1 (en) 1992-02-24 2001-04-10 New England Medical Center Hospitals, Inc. Fibroblast stimulating growth factor 1 (FsF-1) and the early detection of fibrosis

Non-Patent Citations (2)

* Cited by examiner, † Cited by third party
Title
D. CATTY, "Antibodies, Volume 1, A Practical Approach", Published 1989, by IRL PRESS, see pages 19-79. *
JOURNAL OF IMMUNOLOGY, Volume 132, Number 6, issued June 1984, D.J. WYLER et al., "Fibroblast Stimulation in Schistosomiasis", pages 3142-3148. *

Cited By (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6214968B1 (en) 1992-02-24 2001-04-10 New England Medical Center Hospitals, Inc. Fibroblast stimulating growth factor 1 (FsF-1) and the early detection of fibrosis
US6017719A (en) * 1994-06-14 2000-01-25 Nexell Therapeutics, Inc. Positive and positive/negative cell selection mediated by peptide release
WO1996026954A1 (fr) * 1995-02-28 1996-09-06 New England Medical Center Hospitals, Inc. Fsf-1 et la detection precoce des fibroses
WO1996026953A1 (fr) * 1995-02-28 1996-09-06 New England Medical Center Hospitals, Inc. FsF-1 ET LA DETECTION PRECOCE DES FIBROSES

Similar Documents

Publication Publication Date Title
CA1310902C (fr) Facteurs autocrines de motilite pour le diagnostic et le traitement du cancer
Bhardwaj et al. IL-6/IFN-beta 2 in synovial effusions of patients with rheumatoid arthritis and other arthritides. Identification of several isoforms and studies of cellular sources.
CA1241641A (fr) Facteurs osteogenes
RU2432364C2 (ru) ПОЛИКЛОНАЛЬНОЕ АНТИТЕЛО ПРОТИВ Nogo, ФАРМАЦЕВТИЧЕСКАЯ КОМПОЗИЦИЯ И ПРИМЕНЕНИЕ АНТИТЕЛА ДЛЯ ИЗГОТОВЛЕНИЯ ЛЕКАРСТВЕННОГО СРЕДСТВА
JPH06505983A (ja) 創傷治癒の促進方法および促進薬
MacLaughlin et al. Mullerian duct regression and antiproliferative bioactivities of mullerian inhibiting substance reside in its carboxy-terminal domain
EP0662092B1 (fr) Facteur neurotrophique dependant de l'activite
JP3545408B2 (ja) シャペロニン１０
IBRAHIM et al. Reproductive tract secretions and bull spermatozoa contain different clusterin isoforms that cluster cells and inhibit complement‐induced cytolysis
Rosenstreich et al. A human urine-derived interleukin 1 inhibitor. Homology with deoxyribonuclease I.
KR100425627B1 (ko) 포유동물의간으로부터추출된단백질및종양치료와관련한그이용방법
JPH0723398B2 (ja) 初乳由来ポリペプチド因子
Prakash et al. Fibroblast stimulation in schistosomiasis. XI. Purification to apparent homogeneity of fibroblast-stimulating factor-1, an acidic heparin-binding growth factor produced by schistosomal egg granulomas.
Prakash et al. Fibroblast stimulation in schistosomiasis. XII. Identification of CD4+ lymphocytes within schistosomal egg granulomas as a source of an apparently novel fibroblast growth factor (FsF-1)
WO1994014976A1 (fr) Complexe modulateur de la reponse immunitaire, et ses utilisations
CA2176948C (fr) Chaperonine 10
FI91484C (fi) Menetelmä uuden solun kasvua säätelevän tekijän, onkostatiini M:n valmistamiseksi
WO1993016715A1 (fr) Facteur 1 de stimulation de fibroblastes et detection anticipee de la fibrose
US5942220A (en) Inhibitor of cytokine activity and applications thereof
US6559123B1 (en) Tissue-derived tumor growth inhibitors, methods of preparation and uses thereof
US5693481A (en) Inhibitor of cytokine activity and applications thereof
AU593063B2 (en) Purified human angiogenic factor, method for its preparation and pharmaceutical preparations
US20030158115A1 (en) Methods and compositions for detecting and treating kidney diseases associated with adhesion of crystals to kidney cells
US6214968B1 (en) Fibroblast stimulating growth factor 1 (FsF-1) and the early detection of fibrosis
US6482934B1 (en) Methods and compositions for detecting and treating kidney diseases associated with adhesion of crystals to kidney cells

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): JP

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE

COP Corrected version of pamphlet

Free format text: PAGES 3/11-11/11,DRAWINGS,REPLACED BY NEW PAGES 3/11-11/11;AFTER THE RECTIFICATION OF OBVIOUS ERRORS AS AUTHORIZED BY THE UNITED STATES PATENT AND TRADEMARK OFFICE IN ITS CAPACITY AS INTERNATIONAL SEARCHING AUTHORITY

DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
122 Ep: pct application non-entry in european phase